Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity

The aim of this study was to evaluate the visual and structural outcomes of eyes that received ranibizumab as treatment for retinopathy of prematurity (ROP). This was a retrospective case series of infants who received a 0.2 mg (0.02 mL) intravitreal injection of ranibizumab as the primary treatment...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of ophthalmology 2017-10, Vol.52 (5), p.468-474
Main Authors: Ells, Anna L., Wesolosky, Jason D., Ingram, April D., Mitchell, Patrick C., Platt, Alexander S.
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Birth Weight
Female
Gestational Age
Humans
Infant
Infant, Newborn
Infant, Premature
Intravitreal Injections
Laser Coagulation
Male
Ranibizumab - administration & dosage
Refractive Errors - physiopathology
Retinopathy of Prematurity - diagnosis
Retinopathy of Prematurity - drug therapy
Retinopathy of Prematurity - physiopathology
Retrospective Studies
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the visual and structural outcomes of eyes that received ranibizumab as treatment for retinopathy of prematurity (ROP). This was a retrospective case series of infants who received a 0.2 mg (0.02 mL) intravitreal injection of ranibizumab as the primary treatment for type 1 ROP. Outcome measures included regression or recurrence of ROP, complications of treatment, and assessment of visual acuity and refractive error. Forty-two eyes of 21 infants (13 male) were included. Mean gestational age and birth weight were 24.6 ± 1.3 weeks and 613 ± 91 g, respectively. Mean age at injection was 37.4 ± 2.2 weeks postmenstrual age, and mean follow-up period was 10.1 ± 7 months. Active neovascularization regressed rapidly, and anatomical outcomes were favourable in all eyes. Twelve eyes of 6 infants received supplemental laser photocoagulation at a mean post-menstrual age (PMA) of 72.0 ± 27.3 weeks when vascularization had not advanced beyond zone II. Visual acuity was measurable in 28 of 42 eyes. Mean visual acuity was 0.94 ± 0.36 logMAR. Mean spherical equivalent was +1.00. There were no ocular or systemic complications in these patients and no cicatricial complications were observed with no progression to stage 4 or 5 disease. A single intravitreal dose of 0.2 mg (0.02 mL) ranibizumab showed favourable anatomical and functional outcomes in eyes with type 1 ROP. Cette étude visait à évaluer résultats visuels et structurels obtenus avec le ranibizumab dans le traitement de la rétinopathie du prématuré (RDP). Examen rétrospectif d’une série de cas. Des nourrissons atteints de RDP de type 1 ont reçu, à titre de traitement principal, 0,2 mg (0,02 mL) de ranibizumab en injection intravitréenne. Les paramètres évalués comprenaient la régression ou la récurrence de la RDP, les complications du traitement, l’acuité visuelle et le vice de réfraction. L’examen a porté sur 42 yeux de 21 nourrissons (13 garçons). L’âge gestationnel et le poids de naissance moyens étaient de 24,6 ± 1,3 semaines et de 613 ± 91 g, respectivement. L’âge moyen au moment de l’injection était de 37,4 ± 2,2 semaines d'âge postmenstruel (APM), et la durée moyenne du suivi, de 10,1 ± 7 mois. La néovascularisation active a régressé rapidement, et les résultats anatomiques ont été favorables dans tous les yeux. On a procédé à une photocoagulation au laser en appoint au traitement dans 12 yeux de 6 nourrissons, dont l’APM moyen était de 72,0 ± 27,3 semaines, alors que la v
ISSN:0008-4182
1715-3360
DOI:10.1016/j.jcjo.2017.02.012